Our study demonstrates that both CDDO-TFEA and CDDO-Me are very potent dual KEAP1 and BACH1 inhibitors, and that they reduce lung cancer cell invasion in a BACH1-dependent and NRF2-independent manner. This evidence concerns the gene NFE2L2 and lung carcinoma.